1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C.
Addressing common questions encountered in the diagnosis and
management of cardiac amyloidosis. Circulation 2017; 135:
1357 – 1377.
2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS.
Transthyretin amyloid cardiomyopathy: JACC state-of-the-art
review. J Am Coll Cardiol 2019; 73: 2872 – 2891.
3. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T,
et al. JCS 2020 guideline on diagnosis and treatment of cardiac
amyloidosis. Circ J 2020; 84: 1610 – 1671.
4. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato
A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC working group on myocardial and
pericardial diseases. Eur Heart J 2021; 42: 1554 – 1568.
5. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016; 387: 2641 – 2654.
6. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson
LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101: 395 – 400.
7. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile
systemic amyloidosis presenting with heart failure: A comparison
with light chain-associated amyloidosis. Arch Intern Med 2005;
165: 1425 – 1429.
8. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL,
et al. Heart failure resulting from age-related cardiac amyloid
disease associated with wild-type transthyretin: A prospective,
observational cohort study. Circulation 2016; 133: 282 – 290.
9. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin
G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am
Coll Cardiol 2016; 68: 1014 – 1020.
10. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T,
Ueda M, et al. Long-term survival after liver transplantation in
patients with familial amyloid polyneuropathy. Neurology 2012;
78: 637 – 643.
11. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y,
Iijima M, et al. Natural history of transthyretin val30 met familial amyloid polyneuropathy: Analysis of late-onset cases from
non-endemic areas. J Neurol Neurosurg Psychiatry 2012; 83:
152 – 158.
12. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini
G, Waddington-Cruz M, et al. Tafamidis treatment for patients
with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;
379: 1007 – 1016.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A,
Ernande L, et al. Recommendations for cardiac chamber quantifica-
14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. tion by echocardiography in adults: An update from the American
Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;
16: 233 – 270.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E,
Sachs I, et al. Echocardiographic assessment of left ventricular
hypertrophy: Comparison to necropsy findings. Am J Cardiol
1986; 57: 450 – 458.
Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna
M, Plana JC, et al. Relative apical sparing of longitudinal strain
using two-dimensional speckle-tracking echocardiography is
both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442 – 1448.
Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T,
et al. Early experience of tafamidis treatment in japanese patients
with wild-type transthyretin cardiac amyloidosis from the Kochi
amyloidosis cohort. Circ J 2022; 86: 1121 – 1128.
Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, et
al. Tafamidis treatment delays structural and functional changes
of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 2022; 23: 767 – 780.
Giblin GT, Cuddy SAM, Gonzalez-Lopez E, Sewell A, Murphy
A, Dorbala S, et al. Effect of tafamidis on global longitudinal
strain and myocardial work in transthyretin cardiac amyloidosis.
Eur Heart J Cardiovasc Imaging 2022; 23: 1029 – 1039.
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de
Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type
transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585 – 2594.
Tanaka H. Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: Special focus on speckletracking longitudinal strain. J Echocardiogr 2021; 19: 71 – 79.
Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern
R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis
and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur
Heart J 2017; 38: 2879 – 2887.
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik
M, Dona C, et al. Prevalence and outcomes of concomitant
aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021;
77: 128 – 139.
Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran
S, et al. Characteristics and natural history of early-stage cardiac
transthyretin amyloidosis. Eur Heart J 2022; 43: 2622 – 2632.
Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL,
Lenihan DJ, et al. Long-term survival with tafamidis in patients
with transthyretin amyloid cardiomyopathy. Circ Heart Fail
2022; 15: e008193.
Circulation Journal Vol.87, April 2023
...
論文の公開元へ
